Harmony Biosciences is a biotechnology business based in the US. Harmony Biosciences shares (HRMY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $34.17 – a decrease of 2.57% over the previous week. Harmony Biosciences employs 268 staff and has a trailing 12-month revenue of around $744.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $34.17 |
|---|---|
| 52-week range | $26.47 - $41.61 |
| 50-day moving average | $31.82 |
| 200-day moving average | $34.61 |
| Wall St. target price | $51.56 |
| PE ratio | 13.7061 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $2.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.17 from 2025-05-23
| 1 week (2025-05-16) | -2.57% |
|---|---|
| 1 month (2025-04-25) | 15.40% |
| 3 months (2025-02-25) | -7.57% |
| 6 months (2024-11-25) | -1.56% |
| 1 year (2024-05-24) | 14.09% |
|---|---|
| 2 years (2023-05-25) | -5.06% |
| 3 years (2022-05-25) | 43.2 |
| 5 years (2020-05-21) | N/A |
Valuing Harmony Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harmony Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harmony Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Harmony Biosciences shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Harmony Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $219 million.
The EBITDA is a measure of a Harmony Biosciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $744.9 million |
|---|---|
| Operating margin TTM | 30.45% |
| Gross profit TTM | $583.5 million |
| Return on assets TTM | 12.81% |
| Return on equity TTM | 24.71% |
| Profit margin | 20.5% |
| Book value | $12.55 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Harmony Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Harmony Biosciences's shares have ranged in value from as little as $26.47 up to $41.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harmony Biosciences's is 0.818. This would suggest that Harmony Biosciences's shares are less volatile than average (for this exchange).
Harmony Biosciences Holdings, Inc. , a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1. 15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Learn how and where to buy Fannie Mae (FNMA) stock, view trends and see what may be ahead for share holders.
See how and where to buy Freddie Mac (FMCC) stock, view past price performance and learn what’s ahead for shareholders.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
It can help reduce taxes owed, but it’s not for beginners.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.